The Evolving Treatment Landscape in Hepatocellular Carcinoma: New Agents and the Role of Biomarkers in First-Line Treatment




Hepatocellular carcinoma (HCC) is a serious tumor type associated with substantial morbidity and mortality. Yet, for more than 10 years, the multikinase inhibitor sorafenib was the only systemic therapy approved by the U.S. Food & Drug Administration (FDA) for the treatment of HCC. Since 2017, however, five additional agents have received FDA approval: lenvatinib as first-line HCC therapy, and regorafenib, nivolumab, pembrolizumab, and cabozantinib as second-line HCC therapy. Given the recent expansion of HCC systemic therapy options, renewed educational endeavors are clearly needed.


Eileen M. O’Reilly, MD
Winthrop Rockefeller Endowed Chair in Medical Oncology
Section Head Hepatopancreaticobiliary & Neuroendocrine Cancers
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York

Release date: February 10, 2020
Expiration date: February 10, 2021
Estimated time to complete activity: 30 minutes


The goals of this Twitter-based Plot-Your-Own-Course CME activity are to provide clinicians with current, clinically applicable information on the evolving treatment landscape in HCC, with a focus on the efficacy and safety of available agents in the first-line setting, the management of treatment-related adverse events, and the research efforts currently underway to identify relevant predictive biomarkers.


Medical oncologists, interventional radiologists, radiologists, gastroenterologists, and oncology advanced practice providers, as well as nurses and other professionals involved in the management of patients with HCC.


Upon completion of this educational activity, participants will be able to:

  • Discuss efficacy and safety data from key clinical trials evaluating the use of new agents in first-line HCC treatment settings
  • Implement strategies to identify, monitor, and manage treatment-related AEs

There are no fees for participating and receiving CME credit for this activity. During the period of February 10, 2020 through February 10, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better.




Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.


Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Eileen M. O’Reilly, MD
Consulting Fees: 3DMedcare, Agios, Alignmed, Amgen, Antengene, Aptus, Aslan, Astellas, Astra Zeneca, Bayer, Beigene, Bioline, BMS, Boston Scientifc, Bridgebio, Carsgen, Celgene, Casi, Cipla, CytomX, Daiichi, Debio, Delcath, Eisai, Exelixis, Flatiron, Genoscience, Halozyme, Hengrui, Incyte, Inovio, Ipsen, Jazz, Jansen, Klus, Kyowa Kirin, LAM, Lilly, Loxo, Merck, Mina, Novella, Onxeo, PCI Biotech, Pfizer, Pieris, QED, Redhill, Sanofi, Servier, Silenseed, Sillajen, Sobi, Targovax, Tekmira, Twoxar, Vicus, Yakult, Yiviva

Contracted Research: ActaBiologica, Agios, Array, Astra Zeneca, Bayer, Beigene, BMS, Casi, Celgene, Exelixis, Genentech, Halozyme, Incyte, Lilly, Mabvax, Novartis, OncoQuest, Polaris Puma, QED, Roche

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc., Eisai, and Merck Sharp & Dohme Corp. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)


Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10
Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.


Provided by Integrity Continuing Education, Inc.


Supported by educational grants from Eisai and Merck & Co., Inc.


Continue to Pretest